Corbus Pharmaceuticals (NASDAQ: CRBP)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.060 | -0.070 | -0.0100 | ||||
REV | 100.000K | 0 | -100.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Corbus Pharmaceuticals (NASDAQ: CRBP) through any online brokerage.
Other companies in Corbus Pharmaceuticals’s space includes: Brooklyn (NASDAQ:BTX), Humanigen (NASDAQ:HGEN), Applied Genetic (NASDAQ:AGTC), NexImmune (NASDAQ:NEXI) and ABVC BioPharma (NASDAQ:ABVC).
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by HC Wainwright & Co. on Thursday, October 8, 2020. The analyst firm set a price target for 3.00 expecting CRBP to rise to within 12 months (a possible 1295.35% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Corbus Pharmaceuticals (NASDAQ: CRBP) is $0.215 last updated August 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Corbus Pharmaceuticals.
Corbus Pharmaceuticals’s Q3 earnings are confirmed for Friday, November 11, 2022.
There is no upcoming split for Corbus Pharmaceuticals.
Corbus Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.